Novartis Ag Earnings

Novartis Ag’s revenue jumped 14.13% since last year same period to $14279.67Mn in the Q2 2025. On a quarterly growth basis, Novartis Ag has generated 4.84% jump in its revenue since last 3-months.

Novartis Ag’s net profit fell -99.88% since last year same period to $4.02Mn in the Q2 2025. On a quarterly growth basis, Novartis Ag has generated -99.89% fall in its net profits since last 3-months.

Novartis Ag’s net profit margin fell -99.89% since last year same period to 0.03% in the Q2 2025. On a quarterly growth basis, Novartis Ag has generated -99.89% fall in its net profit margins since last 3-months.

Novartis Ag’s price-to-earnings ratio after this Q2 2025 earnings stands at 18.09.

Novartis Ag’s earning per share (EPS) estimates for the current quarter stand at 2.3 - a -2.95% fall from last quarter’s estimates.

Novartis Ag’s earning per share (EPS) estimates for the current year stand at 2.3.

Novartis Ag’s earning per share (EPS) jumped 22.84% since last year same period to 2.42 in the Q2 2025. This indicates that the Novartis Ag has generated 22.84% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Novartis Ag’s return on assets (ROA) stands at 0.12.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Novartis Ag’s return on equity (ROE) stands at 0.32.